1. Beta-2-microglobulin (B2M) expression in the urinary sediment correlates with clinical markers of kidney disease in patients with type 1 diabetes 
Maria Beatriz Monteiro, Karina Thieme, Daniele Pereira Santos-Bezerra, Márcia Silva Queiroz, Viktoria Woronik, Marisa Passarelli, Ubiratan Fabres Machado, Daniel Giannella-Neto, Maria Oliveira-Souza, Maria Lúcia Corrêa-Giannella 
Metabolism - Clinical and Experimental 
Volume 65, Issue 6, Pages (June 2016)
DOI: /j.metabol
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Fig. 1
Expression of SGLT2 (SLC5A2) and podocin (NPHS2) in healthy controls, in patients with type 1 diabetes (T1D) and with focal and segmental glomerulosclerosis (FSGS). mRNA expression of SLC5A2 (SGLT2, Panels A and B) and NPHS2 (podocin, Panels C and D) normalized by ELF1 gene. The horizontal line within the box plot represents the median value, and the bars refer to 25th to 75th interquartile range for mRNA levels.
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Fig. 2
Expression of SGLT2 (SLC5A2) and podocin (NPHS2) in type 1 diabetes patients according to diabetic nephropathy (DN) status. mRNA expression of SLC5A2 (SGLT2, Panel A) and NPHS2 (Podocin, Panel B) normalized by ELF1 gene expression in type 1 diabetes patients according to the presence or absence of DN. The horizontal line within the box plot represents the median value, and the bars refer to 25th to 75th interquartile range for mRNA levels.
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Fig. 3
Expression of B2M in healthy controls, in patients with type 1 diabetes (T1D) and with focal segmental glomerulosclerosis (FSGS). mRNA expression of B2M in the control group, in patients with T1D and with FSGS (Panel A); mRNA expression of B2M in the control group plus T1D patients without diabetic nephropathy (DN) versus patients with FSGS plus T1D patients with DN (Panel B). The horizontal line within the box plot represents the median value, and the bars refer to 25th to 75th interquartile range for mRNA levels.
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

5. Fig. 4
Expression of B2M according to diabetic nephropathy (DN) status. mRNA expression of B2M normalized by ELF1 gene expression in type 1 diabetes patients according to the presence or absence of DN. The horizontal line within the box plot represents the median value, and the bars refer to 25th to 75th interquartile range for mRNA levels.
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

6. Fig. 5
Correlations between B2M mRNA expression and urinary albumin-to-creatinine ratio or estimated glomerular filtration rate (eGFR). Correlations between B2M mRNA expression and urinary albumin-to-creatinine ratio (Panel A) or eGFR (Panel B) in the overall type 1 diabetes population. Panels C and D depict, respectively, the correlations between B2M mRNA expression and eGFR in female and male type 1 diabetes patients (r=Spearman's rank correlation coefficient).
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

7. Fig. 6
Expression of B2M in HEK-293 cells exposed or not to 25mM glucose and to albumin. mRNA expression of B2M normalized by 18S gene expression in HEK-293 cells exposed for 72h to control medium (C); 1mg/mL of albumin (Alb); 25mM glucose (HG) or 25mM glucose +1mg/mL albumin (HG+Alb). The horizontal line within the box plot represents the median value, and the bars include the 25th to 75th interquartile range for mRNA levels.
Metabolism - Clinical and Experimental  , DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions